CD22 / Luciferase - CHO Recombinant Cell Line | 79715

CD22 / Luciferase - CHO Recombinant Cell Line | 79715 | Gentaur US, UK & Europe Disrtribition

Category: CAR-T/Cell Line

Application: Useful for screening and validating antibodies against CD22 and different CD22 CAR-T for immunotherapy research and drug discovery.

Background: CD22, also known as Siglec-2, is expressed on the membrane of B-cells. It is reported to act as an inhibitory co-receptor of the B-cell receptor to control the body's B-cell response. In 2017 the FDA approved inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate targeting CD22, for patients with B-cell acute lymphoblastic leukemia (ALL). Additional therapies targeting CD22 are under evaluation.

Description: Recombinant clonal stable CHO cell line constitutively expressing full length human CD22 protein (Genbank #NM_001771) and the firefly luciferase. Surface expression of CD22 was confirmed by flow cytometry.

Product Type: Cell Line

Shippement Condition: -80°C